Immunogen (IMGN) Misses Q4 EPS by 12c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
ImmunoGen Reports Fourth Quarter and Fiscal Year 2016 Financial Results and Provides Quarterly Business Update
August 4, 2016 6:30 AM EDTConference call at 8:00 am ET today
Following positive meeting with FDA, Phase 3 FORWARD I study of mirvetuximab soravtansine in patients with platinum-resistant ovarian cancer on track to begin before year end. Mirvetuximab soravtansine plus Avastin® combination regimen advanced to Phase 2 in FORWARD II trial. Phase 1 testing of IMGN779 the first ADC deploying an ImmunoGen DNA-alkylating payload initiated in patients with acute myeloid leukemia (AML). Recent appointment of Mark Enyedy as President and CEO brings proven leadership and deep experience building oncology... More